SAN Sanofi

Sanofi: information concerning the total number of voting rights and shares, February 2020

Sanofi: information concerning the total number of voting rights and shares, February 2020

  

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,507,692,222 €

Registered office : 54, rue La Boétie – 75008 Paris – France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date  



Total number of

issued shares



  		Number of real

voting rights

(excluding treasury shares) 		Theoretical number of

voting rights

(including treasury shares)*
February 29, 2020 1,254,420,040 1,402,565,633 1,406,567,108

*  Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

Europe Tel: 45  US Tel: 0

e-mail:



 



Media Relations Department

Tel: 46

 e-mail:



 

 

Attachment

EN
26/03/2020

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press Release: Tzield approved in China as first disease-modifying the...

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes         Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 T1D in adult and pediatric patients aged eight years and older, with stage 2 T1D compared to placeboAdditional regulatory reviews are ongoing across different disease stages by regulatory authorities around the world Paris, Septembe...

8h / 1m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Tzield approuvé en Chine comme premier traiteme...

Communiqué de presse : Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2 Tzield approuvé en Chine comme premier traitement modificateur de la maladie pour les patients adultes et pédiatriques atteints de diabète de type 1 au stade 2 Approbation basée sur l’étude TN-10, qui démontre la capacité du Tzield à retarder l’apparition du DT1 de stade 3 chez les patients adultes et pédiatriques âgés de huit ans et plus, avec un DT1 de stade 2 par rapport au placeboDes examens réglementaires...

8h / 1m 1 EN
Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
EUR 4270.00
SAN SANOFI

Sanofi - Downgrade to HOLD (TP EUR78 [125], 25pgs)

Our downgrade is predicated on 4 things: 1) Following the weak amlitelimab data, the Dupixent LOE needs to be explicitly modelled given that it will be encompassed in forecasts within a few months, 2) Our work shows that the REGN Alliance is unlikely to be restructured which could have favoured Sanofi in the S-T with more of the Dupi economics, 3) There are growing headwinds for Vaccines & RSV, & 4) Lack of catalysts. Blowout data from tolebrutinib is the only thing that could change our view in...

09/08/25 September 8, 2025 1 EN
Rafael Bonardell
  • Rafael Bonardell
EUR 50.00
SAN SANOFI

SANOFI: CAÍDA TRAS LOS RESULTADOS DE AMLITELIMAB (ANÁLISIS BANCO SABAD...

SANO cae tras la publicación de los Rdos. de Amlitelimab pese a que estos han cumplido todos los objetivos del estudio.

09/04/25 September 4, 2025 1 ES
Martin Marandon-Carlhian ... (+4)
  • Martin Marandon-Carlhian
  • Oliver Metzger
  • Sinan Doganli
  • Stephane Houri
IFX INFINEON TECHNOLOGIES AG
FME FRESENIUS MEDICAL CARE AG
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
KPN ROYAL KPN NV
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
NOVN NOVARTIS AG
EVT EVOTEC SE
EN BOUYGUES SA
HNR1 HANNOVER RUECK SE
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
GLJ GRENKE AG
UTDI UNITED INTERNET AG
ELG ELMOS SEMICONDUCTOR SE
SDF K+S AG
ZAL ZALANDO SE
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
DTE DEUTSCHE TELEKOM AG
TLX TALANX AG
IMPN IMPLENIA AG
AIXA AIXTRON SE
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
BC8 BECHTLE AG
ADN1 ADESSO AG
SAX STROEER SE & CO. KGAA
EVK EVONIK INDUSTRIES AG
WAF SILTRONIC AG
SMHN SUESS MICROTEC AG
FNTN FREENET AG
AZN ASTRAZENECA PLC
BIM BIOMERIEUX SA
DUE DURR AG
BFSA BEFESA SA
SANT S&T AG
AEIN ALLGEIER HOLDING AG
HAG HENSOLDT AG
NA9 NAGARRO
FPE3 FUCHS PETROLUB SE
SPAC 468 SPAC I SE
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
09/04/25 September 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch